Showing 5261-5270 of 7117 results for "".
- Researchers Analyze Social Media Posts on JAK Inhibitorshttps://practicaldermatology.com/news/researchers-analyze-social-media-posts-jak-inhibitors/2468227/An analysis of social media posts concluded that patients are most concerned about the efficacy and side effects of JAK inhibitors and issues regarding access to them, according to a new Archive of Dermatological Research article by members of the University of Nebraska Medical Center’s Departmen
- Organon to Acquire VTAMA Maker Dermavanthttps://practicaldermatology.com/news/organon-acquire-vtama-maker-dermavant/2468226/Organon and Dermavant Sciences Ltd. announced that they have entered into a definitive agreement, under which Organon will acquire Dermavant, a Roivant company whose product VTAMA® (tapinarof) cream, 1%, for the topical treatment of mild, moderate, and severe plaque psoriasis in adults was approv
- Study: Adherence Declines With Complex Atopic Dermatitis Regimenshttps://practicaldermatology.com/news/dherence-declines-complex-atopic-dermatitis-regimens-aad-guidelines/2468194/New American Academy of Dermatology (AAD) guidelines emphasize complex topical regimens for atopic dermatitis (AD), but adherence issues may limit their effectiveness, according to new research. According to a recent article in the Journal of Drugs in Dermatology, the AAD released
- Cord Blood Biomarkers and TEWL Predict Atopic Dermatitis in Infantshttps://practicaldermatology.com/news/cord-blood-biomarkers-and-tewl-predict-atopic-dermatitis-infants/2468171/A prospective study reports that elevated levels of CCL17 and IL-31 in cord blood, along with increased transepidermal water loss (TEWL) at the anterior cubital fossa, could help identify infants at higher risk of developing atopic dermatitis (AD) within their first year of life. The study
- Study Identifies Key Patient-Centered Attributes of Atopic Dermatitis Flarehttps://practicaldermatology.com/news/study-identifies-key-patient-centered-attributes-ad-flare/2468156/A new study revealed a consensus on the patient-centered definition of an atopic dermatitis (AD) flare. Researchers for the study recruited 26 participants for focus groups and 631 participants for a survey through the National Eczema Association. The participants rated various attributes
- Tralokinumab Safe for Special Atopic Dermatitis Populationshttps://practicaldermatology.com/news/tralokinumab-found-safe-special-ad-populations/2468141/A recent retrospective study indicated that tralokinumab was linked with significant improvements in atopic dermatitis (AD) in special populations (SPs) such as the elderly and those with significant comorbidities. Researchers investigating the efficacy and safe
- Study: Melanoma Declining Among Ages 30-59 in Swedenhttps://practicaldermatology.com/news/study-melanoma-declining-among-ages-30-59-sweden/2468114/Melanoma incidence and mortality rates have declined in recent years among 30- to 59-year-olds in Sweden, according to a recent study published in JAMA Dermatology. A cohort study involving Sweden’s entire population found a continuous rise in primary invasive cutaneous melanoma incidence
- Two New Options for After-Sun Care Launchedhttps://practicaldermatology.com/news/two-new-options-after-sun-care-launched/2467968/San Diego-based skincare company Terns announced today that it has launched two new after-sun care products targeting outdoor enthusiasts. The products, which include a range of creams and gels, are formulated with the proprietary Sirenas Complex, which the manufacturer said is derived f
- Study Analyzes Genes Targeted by NB-UVB for Atopic Dermatitishttps://practicaldermatology.com/news/study-analyzes-genes-targeted-nb-uvb-ad/2467966/Applied narrowband ultraviolet B (NB-UVB) radiation is likely a suitable therapeutic method for atopic dermatitis, according to a network analysis in the Journal of Lasers in Medical Sciences. The study, undertaken by researchers in Iran, aimed to explore the critical genes that are target
- Review: No Safety Concerns for Live Vaccines with Dupilumabhttps://practicaldermatology.com/news/systematic-review-no-safety-concerns-live-vaccines-dupilumab/2467944/Live vaccines are likely safe and effective for patients undergoing dupilumab treatment, according to results from a systematic review and expert consensus. Authors for a new systematic review, combined with expert input from a Delphi panel, provided insights into the safety and efficacy o